Cargando…
Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer
The aim of this study was to develop a noninvasive serological diagnostic approach in identifying and evaluating a panel of candidate autoantibodies to tumor‐associated antigens (TAAs) based on protein microarray technology for early detection of ovarian cancer (OC). Protein microarray based on 154...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894002/ https://www.ncbi.nlm.nih.gov/pubmed/33185955 http://dx.doi.org/10.1111/cas.14732 |
_version_ | 1783653162142400512 |
---|---|
author | Ma, Yan Wang, Xiao Qiu, Cuipeng Qin, Jiejie Wang, Keyan Sun, Guiying Jiang, Di Li, Jitian Wang, Lin Shi, Jianxiang Wang, Peng Ye, Hua Dai, Liping Jiang, Bing‐Hua Zhang, Jianying |
author_facet | Ma, Yan Wang, Xiao Qiu, Cuipeng Qin, Jiejie Wang, Keyan Sun, Guiying Jiang, Di Li, Jitian Wang, Lin Shi, Jianxiang Wang, Peng Ye, Hua Dai, Liping Jiang, Bing‐Hua Zhang, Jianying |
author_sort | Ma, Yan |
collection | PubMed |
description | The aim of this study was to develop a noninvasive serological diagnostic approach in identifying and evaluating a panel of candidate autoantibodies to tumor‐associated antigens (TAAs) based on protein microarray technology for early detection of ovarian cancer (OC). Protein microarray based on 154 proteins encoded by 138 cancer driver genes was used to screen candidate anti‐TAA autoantibodies in a discovery cohort containing 17 OC and 27 normal controls (NC). Indirect enzyme‐linked immunosorbent assay (ELISA) was used to detect the content of candidate anti‐TAA autoantibodies in sera from 140 subjects in the training cohort. Differential anti‐TAA autoantibodies were further validated in the validation cohort with 328 subjects. Subsequently, 112 sera from the patients with ovarian benign diseases with 104 OC sera and 104 NC sera together were recruited to identify the specificity of representative autoantibodies to OC among ovarian diseases. Five TAAs (GNAS, NPM1, FUBP1, p53, and KRAS) were screened out in the discovery phase, in which four of them presented higher levels in OC than controls (P < .05) in the training cohort, which was consistent with the result in the subsequent validation cohort. An optimized panel of three anti‐TAA (GNAS, p53, and NPM1) autoantibodies was identified to have relatively high sensitivity (51.2%), specificity (86.0%), and accuracy (68.6%), respectively. This panel can identify 51% of OC patients with CA125 negative. This study supports our assumption that anti‐TAA autoantibodies can be considered as potential diagnostic biomarkers for detection of OC; especially a panel of three anti‐TAA autoantibodies could be a good tool in immunodiagnosis of OC. |
format | Online Article Text |
id | pubmed-7894002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78940022021-03-02 Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer Ma, Yan Wang, Xiao Qiu, Cuipeng Qin, Jiejie Wang, Keyan Sun, Guiying Jiang, Di Li, Jitian Wang, Lin Shi, Jianxiang Wang, Peng Ye, Hua Dai, Liping Jiang, Bing‐Hua Zhang, Jianying Cancer Sci Original Articles The aim of this study was to develop a noninvasive serological diagnostic approach in identifying and evaluating a panel of candidate autoantibodies to tumor‐associated antigens (TAAs) based on protein microarray technology for early detection of ovarian cancer (OC). Protein microarray based on 154 proteins encoded by 138 cancer driver genes was used to screen candidate anti‐TAA autoantibodies in a discovery cohort containing 17 OC and 27 normal controls (NC). Indirect enzyme‐linked immunosorbent assay (ELISA) was used to detect the content of candidate anti‐TAA autoantibodies in sera from 140 subjects in the training cohort. Differential anti‐TAA autoantibodies were further validated in the validation cohort with 328 subjects. Subsequently, 112 sera from the patients with ovarian benign diseases with 104 OC sera and 104 NC sera together were recruited to identify the specificity of representative autoantibodies to OC among ovarian diseases. Five TAAs (GNAS, NPM1, FUBP1, p53, and KRAS) were screened out in the discovery phase, in which four of them presented higher levels in OC than controls (P < .05) in the training cohort, which was consistent with the result in the subsequent validation cohort. An optimized panel of three anti‐TAA (GNAS, p53, and NPM1) autoantibodies was identified to have relatively high sensitivity (51.2%), specificity (86.0%), and accuracy (68.6%), respectively. This panel can identify 51% of OC patients with CA125 negative. This study supports our assumption that anti‐TAA autoantibodies can be considered as potential diagnostic biomarkers for detection of OC; especially a panel of three anti‐TAA autoantibodies could be a good tool in immunodiagnosis of OC. John Wiley and Sons Inc. 2020-12-03 2021-02 /pmc/articles/PMC7894002/ /pubmed/33185955 http://dx.doi.org/10.1111/cas.14732 Text en © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/3.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Ma, Yan Wang, Xiao Qiu, Cuipeng Qin, Jiejie Wang, Keyan Sun, Guiying Jiang, Di Li, Jitian Wang, Lin Shi, Jianxiang Wang, Peng Ye, Hua Dai, Liping Jiang, Bing‐Hua Zhang, Jianying Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer |
title | Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer |
title_full | Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer |
title_fullStr | Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer |
title_full_unstemmed | Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer |
title_short | Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer |
title_sort | using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894002/ https://www.ncbi.nlm.nih.gov/pubmed/33185955 http://dx.doi.org/10.1111/cas.14732 |
work_keys_str_mv | AT mayan usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT wangxiao usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT qiucuipeng usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT qinjiejie usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT wangkeyan usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT sunguiying usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT jiangdi usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT lijitian usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT wanglin usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT shijianxiang usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT wangpeng usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT yehua usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT dailiping usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT jiangbinghua usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer AT zhangjianying usingproteinmicroarraytoidentifyandevaluateautoantibodiestotumorassociatedantigensinovariancancer |